246 related articles for article (PubMed ID: 36983444)
1. Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice.
Bosco G; Di Giacomo Barbagallo F; Spampinato S; Lanzafame L; Di Pino A; Piro S; Purrello F; Scicali R
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983444
[TBL] [Abstract][Full Text] [Related]
2. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
Agabiti Rosei E; Salvetti M
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
[TBL] [Abstract][Full Text] [Related]
3. Lipid-lowering approaches to manage statin-intolerant patients.
Ruscica M; Bertoletti A; Gobbi C; Sirtori CR; Carugo S; Corsini A
Eur Heart J Suppl; 2024 Apr; 26(Suppl 1):i56-i59. PubMed ID: 38867860
[TBL] [Abstract][Full Text] [Related]
4. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance.
Koskinas K; Wilhelm M; Windecker S
Swiss Med Wkly; 2016; 146():w14333. PubMed ID: 27400448
[TBL] [Abstract][Full Text] [Related]
5. Umbrella Review on Non-Statin Lipid-Lowering Therapy.
Beshir SA; Hussain N; Elnor AA; Said ASA
J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):437-452. PubMed ID: 33836639
[TBL] [Abstract][Full Text] [Related]
6. Inclisiran: A Review in Hypercholesterolemia.
Frampton JE
Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996
[TBL] [Abstract][Full Text] [Related]
7. Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.
Schreml J; Gouni-Berthold I
Curr Med Chem; 2018; 25(13):1538-1548. PubMed ID: 28618994
[TBL] [Abstract][Full Text] [Related]
8. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy.
Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
Clin Cardiol; 2014 Mar; 37(3):131-9. PubMed ID: 24477778
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial.
Moriarty PM; Jacobson TA; Bruckert E; Thompson PD; Guyton JR; Baccara-Dinet MT; Gipe D
J Clin Lipidol; 2014; 8(6):554-561. PubMed ID: 25499937
[TBL] [Abstract][Full Text] [Related]
10. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
11. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
Nissen SE; Dent-Acosta RE; Rosenson RS; Stroes E; Sattar N; Preiss D; Mancini GB; Ballantyne CM; Catapano A; Gouni-Berthold I; Stein EA; Xue A; Wasserman SM; Scott R; Thompson PD;
Clin Cardiol; 2016 Mar; 39(3):137-44. PubMed ID: 26946077
[TBL] [Abstract][Full Text] [Related]
12. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
[TBL] [Abstract][Full Text] [Related]
13. PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance.
Voutyritsa E; Damaskos C; Farmaki P; Kyriakos G; Diamantis E; Quiles-SÁnchez LV; Garmpi A; Garmpis N; Patsouras A; Stelianidi A; Savvanis S
In Vivo; 2021; 35(1):61-68. PubMed ID: 33402450
[TBL] [Abstract][Full Text] [Related]
14. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
[TBL] [Abstract][Full Text] [Related]
15. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
16. Bempedoic acid: Review of a novel therapy in lipid management.
Delevry D; Gupta EK
Am J Health Syst Pharm; 2021 Jan; 78(2):95-104. PubMed ID: 33399194
[TBL] [Abstract][Full Text] [Related]
17. Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries.
Nishikido T; Ray KK
Front Cardiovasc Med; 2018; 5():199. PubMed ID: 30761308
[TBL] [Abstract][Full Text] [Related]
18. Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid.
Mehta V; Puri R; Duell PB; Iyengar SS; Wong ND; Yusuf J; Mukhopadhyay S; Pradhan A; Muruganathan A; Wangnoo SK; Kapoor D; Rastogi A; Tiwaskar MH; Mahajan K; Narasingan SN; Agarwala R; Bordoloi N; Soumitra K; Chakraborty R; Shetty S; Saboo B; Khan A; Prabhakar D; Khanna NN; Mehta A; Bansal M; Kasliwal R; Mehrotra R; Chag M; Sheikh A; Sattur GB; Manoria PC; Pareek KK; Pancholia AK; Melinker RP; Nanda R; Kalra D
J Assoc Physicians India; 2022 Sep; 70(9):11-12. PubMed ID: 36082889
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy.
Tomlinson B; Chan P; Zhang Y; Lam CWK
Expert Opin Pharmacother; 2020 Dec; 21(17):2137-2151. PubMed ID: 32772741
[TBL] [Abstract][Full Text] [Related]
20. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]